found elevated VISTA expression on peripheral blood monocytes in patients with metastatic prostate cancer receiving ipilimumab (anti CTLA-4 mAb) treatment suggesting VISTA’s inhibitory function may be relevant in advanced prostatic cancer (127). Here, VSIR is linked to prostate cancer.